Sugi Predict

Sugi Predict / Compounds / SCHEMBL1672474

SCHEMBL1672474

SCHEMBL1672474

CNc1nc(C)cc(Cl)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ CACNA1B Q00975 1/20 0.50
▸ APBA1 Q02410 1/20 0.50
▸ KMT2A Q03164 2/20 0.44
▸ CYP1A2 P05177 2/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ HTT P42858 1/20 0.40
▸ NOS3 P29474 1/20 0.40
▸ NOS2 P35228 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ TERT O14746 1/20 0.37
▸ PDE4A P27815 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1318655 0.85 POLB (0.42) POLBMAPTCACNA1BAPBA1CYP1A2
SCHEMBL3266109 0.83 MAPT (0.53) POLBMAPTCACNA1BAPBA1KMT2A
SCHEMBL12410906 0.77 GAA (0.52) POLBKMT2ACYP1A2CASP1LMNA
SCHEMBL8349356 0.77 KMT2A (0.54) POLBMAPTKMT2ACYP1A2CASP1
SCHEMBL12106760 0.76 MAPT (0.45) POLBMAPTCACNA1BAPBA1KMT2A
SCHEMBL18019132 0.75 POLB (0.41) POLBMAPTKMT2ACYP1A2CASP1
SCHEMBL12499637 0.74 NOS3 (0.58) POLBMAPTCACNA1BAPBA1LMNA
SCHEMBL12963418 0.74 KMT2A (0.50) MAPTKMT2ACYP1A2CASP1LMNA
SCHEMBL6552483 0.74 KMT2A (0.42) MAPTKMT2ACYP1A2CASP1LMNA
SCHEMBL10285741 0.73 MAPT (0.46) POLBMAPTCACNA1BAPBA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN RESEARCH & DEVELOPMENT, LLC 2024-05-16 — — US disclosed
EP-4284801-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES Janssen Biotech, Inc. (US) 2023-12-06 — — EP disclosed
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 — — EP disclosed
WO-2022165529-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN BIOTECH, INC. (US) 2022-08-04 — — WO disclosed
US-20220008418-A1 Aminoquinoline Derivatives and Uses Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-13 — — US disclosed
US-11078165-B2 Compounds for treating tuberculosis NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2021-08-03 — — US disclosed
US-11078165-B2 Compounds for treating tuberculosis NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2021-08-03 — — US disclosed
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2021-07-01 — — US disclosed
WO-2020221894-A1 ANTIVIRAL COMPOUNDS Universität Wien (AT) 2020-11-05 — — WO disclosed
US-20200231550-A1 COMPOUNDS FOR TREATING TUBERCULOSIS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2020-07-23 — — US disclosed
WO-2011050200-A1 FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-04-28 — — WO disclosed
US-20100311775-A1 Novel sEH Inhibitors and Their Use SMITHKLINE BEECHAM CORPORATION (US) 2010-12-09 — — US disclosed
US-20100311776-A1 Novel sEH Inhibitors and their Use SMITHKLINE BEECHAM CORPORATION 2010-12-09 — — US disclosed
EP-2240025-A1 NOVEL sEH INHIBITORS AND THEIR USE GlaxoSmithKline LLC (US) 2010-10-20 — — EP disclosed
WO-2010096314-A1 INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS AMGEN INC. (US) 2010-08-26 — — WO disclosed
WO-2009097475-A1 NOVEL sEH INHIBITORS AND THEIR USE SMITHKLINE BEECHAM CORPORATION (US) 2009-08-06 — — WO disclosed
EP-0422178-B1 PYRIMIDINE DERIVATIVES ZENECA LTD (GB) 1994-10-05 — — EP disclosed
US-5223505-A PYRIMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-29 — — US disclosed
EP-0422178-A1 PYRIMIDINE DERIVATIVES. ICI PLC (GB) 1991-04-17 — — EP disclosed
WO-1990012790-A1 PYRIMIDINE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311776-A1 Novel sEH Inhibitors and their Use EPHX1, NCEH1, FAH POLB 992/4885MAPT 3577/4885CACNA1B 4350/4885
US-20220008418-A1 Aminoquinoline Derivatives and Uses Thereof LRRK2, NLN, AADAT POLB 1716/4885MAPT 525/4885CACNA1B 1260/4885
US-20100311775-A1 Novel sEH Inhibitors and Their Use EPHX1, NCEH1, FAH POLB 1534/4885MAPT 3579/4885CACNA1B 4383/4885
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES SIK2, SIK1, SGK2 POLB 2315/4885MAPT 718/4885CACNA1B 1994/4885
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 POLB 1730/4885MAPT 3035/4885CACNA1B 4139/4885
US-11078165-B2 Compounds for treating tuberculosis ATP5ME, ATP5MG, ATP5F1D POLB 327/4885MAPT 2750/4885CACNA1B 3651/4885
US-20200231550-A1 COMPOUNDS FOR TREATING TUBERCULOSIS ATP5ME, ATP5MG, ATP5F1D POLB 327/4885MAPT 2750/4885CACNA1B 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.